Renal cell cancer, also known as kidney cancer or renal adenocarcinoma, is a disease caused by the presence of malignant or cancerous cells in the lining of tubules in the kidney. Smoking and consumption of certain painkillers for a long duration of time can increase the risk of developing renal cell carcinoma. Renal cell carcinoma is the eighth most common cancer which affects adults, and accounts for 3% to 4% of new and different cancer cases, globally. Statistically, it is the ninth most common cancer in females and the seventh most common cancer in males. Takeda Pharmaceutical Company Ltd. is in the process of developing TAK-228 as a mammalian target of rapamycin (mTOR) inhibitor for the treatment of renal cell carcinoma. Some of the companies having a pipeline of renal cell carcinoma include Takeda Pharmaceutical Company Ltd., Tracon Pharmaceuticals Inc. and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.